BioMarin Pharmaceutical (NASDAQ:BMRN) Upgraded at UBS Group

BioMarin Pharmaceutical (NASDAQ:BMRN) was upgraded by analysts at UBS Group to a “strong-buy” rating in a research report issued to clients and investors on Wednesday, Zacks reports.

Several other equities analysts have also recently commented on the company. Barclays upped their price target on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the company an “overweight” rating in a report on Wednesday. Morgan Stanley lifted their price objective on BioMarin Pharmaceutical from $119.00 to $124.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. HC Wainwright reissued a “neutral” rating and set a $60.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, September 10th. Citigroup boosted their price objective on BioMarin Pharmaceutical from $75.00 to $76.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Finally, BMO Capital Markets restated an “outperform” rating on shares of BioMarin Pharmaceutical in a research note on Wednesday, September 16th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $88.87.

BioMarin Pharmaceutical Stock Performance

Shares of NASDAQ:BMRN traded down $1.37 on Wednesday, hitting $54.68. 2,627,811 shares of the company were exchanged, compared to its average volume of 2,366,833. The company’s 50 day moving average price is $63.01 and its two-hundred day moving average price is $58.66. The firm has a market capitalization of $10.58 billion, a price-to-earnings ratio of 147.78, a PEG ratio of 0.39 and a beta of 0.22. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. BioMarin Pharmaceutical has a one year low of $49.26 and a one year high of $70.98.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.25. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The business had revenue of $989.71 million during the quarter, compared to analysts’ expectations of $932.03 million. During the same quarter last year, the company earned $1.44 earnings per share. The firm’s revenue was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Research analysts expect that BioMarin Pharmaceutical will post 4.10 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Mather Group LLC. grew its stake in shares of BioMarin Pharmaceutical by 71.0% in the 3rd quarter. Mather Group LLC. now owns 2,337 shares of the biotechnology company’s stock valued at $140,000 after purchasing an additional 970 shares during the period. Sanders Morris Harris LLC bought a new position in shares of BioMarin Pharmaceutical during the 3rd quarter worth approximately $240,000. Wedmont Private Capital bought a new position in shares of BioMarin Pharmaceutical during the 3rd quarter worth approximately $222,000. GAMMA Investing LLC boosted its stake in BioMarin Pharmaceutical by 50.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,642 shares of the biotechnology company’s stock valued at $219,000 after buying an additional 1,220 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its position in BioMarin Pharmaceutical by 7.9% in the third quarter. Farther Finance Advisors LLC now owns 8,489 shares of the biotechnology company’s stock valued at $509,000 after acquiring an additional 618 shares during the period. Institutional investors and hedge funds own 98.71% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company that develops and commercializes therapies for rare and serious genetic diseases. The company focuses on conditions with limited treatment options, using approaches that include enzyme replacement therapy, small-molecule medicines, biologics and gene therapy.

Its products include Vimizim for mucopolysaccharidosis type IV A, Naglazyme for mucopolysaccharidosis type VI, Brineura for CLN2 disease, Palynziq and Kuvan for phenylketonuria, and Voxzogo for children with achondroplasia and open growth plates.